#jefferies
Jefferies Sees 2025 as Key Year for CDMO Stocks, Picks Piramal Pharma
Jefferies predicts that 2025 will be a year of reckoning for Contract Development and Manufacturing Organization (CDMO) stocks, where actual earnings performance will determine the sector’s winners and laggards. While CDMO stocks saw remarkable returns in 2024, ranging from 20% to 80%, the brokerage points out that earnings were mixed, with some companies seeing upgrades, while others experienced sharp downgrades. Despite this, investor confidence remains strong, driven by long-term opt
Jefferies Sees 2025 as Key Year for CDMO Stocks, Picks Piramal Pharma
Jefferies predicts that 2025 will be a year of reckoning for Contract Development and Manufacturing Organization (CDMO) stocks, where actual earnings performance will determine the sector’s winners and laggards. While CDMO stocks saw remarkable returns in 2024, ranging from 20% to 80%, the brokerage points out that earnings were mixed, with some companies seeing upgrades, while others experienced sharp downgrades. Despite this, investor confidence remains strong, driven by long-term opt









